Joakim Wijkstrom serves as the Senior Vice President and Chief Marketing Officer at Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of therapies to address high unmet medical needs. In his role, Wijkstrom is responsible for overseeing the company's marketing strategies, brand management, and commercial operations. His leadership has been instrumental in driving the successful launch and growth of Vanda's key products, including Hetlioz for non-24-hour sleep-wake disorder and Fanapt for schizophrenia. Wijkstrom brings a wealth of experience in the pharmaceutical industry, having held various senior marketing and commercial positions at leading companies. Prior to joining Vanda, he served as Vice President of Marketing at Shire Pharmaceuticals, where he played a key role in the successful launch of several products in the neuroscience and rare disease spaces. Earlier in his career, Wijkstrom held positions at Novartis and AstraZeneca, gaining extensive experience in product management, market access, and sales operations. His strategic vision and deep understanding of the healthcare market have been crucial in positioning Vanda as a leader in its therapeutic areas. Under Wijkstrom's leadership, Vanda has seen significant growth in its commercial operations and market presence. He has been recognized for his ability to develop and execute innovative marketing campaigns that effectively reach and engage patients, healthcare providers, and payers. Wijkstrom's commitment to patient-centricity and his focus on delivering value to stakeholders have been key drivers of Vanda's success. As the company continues to expand its pipeline and bring new therapies to market, Wijkstrom's expertise and leadership will be vital in shaping Vanda's future growth and impact in the biopharmaceutical industry.